Dupilumab-induced Conjunctivitis In Atopic Dermatitis Patients Is Associated To An Increase Of Proinflammatory Molecules In Tears.

Dupilumab (DU) is an effective treatment in both atopic dermatitis (AD) and T2 asthma (AS) patients, but is associated to ocular surface alterations in AD subjects only. This side effect might be associated to differences in the immunological infiltration. We investigate the clinical and immunological features in tears of DU-associated conjunctivitis.

https://www.jacionline.org/article/S0091-6749(23)01528-2/abstract?rss=yes

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Carlos Aranda, Carmen Alba, Gustavo Garriga, Laura Zubiaga, Almudena Testera-Montes, Cristobalina Mayorga, Enrique Herrera, Maria Torres Jaen, Jorge Suarez, Ibon Eguiluz Source Type: research